28.58 USD
↘ 0.95 (3.22%)AT CLOSE (11:59 AM EDT)
Roivant Sciences Ltd. Common Shares
ROIVNASDAQ • USD
28.58
↘ 0.01 (0.02%)
POST MARKET (AS OF 07:24 PM EDT)
Post Market
AS OF 07:24 PM EDT
28.58
↘ 0.01 (0.02%)
Market: CLOSED
Open?$29.51
High?$29.64
Low?$28.56
Prev. Close?$29.53
Volume?4.6M
Avg. Volume?6.1M
VWAP?$29.15
Rel. Volume?0.77x
Bid / Ask
Bid?$28.10 × 100
Ask?$30.25 × 400
Spread?$2.15
Midpoint?$29.18
Valuation & Ratios
Market Cap?20.6B
Shares Out?719.3M
Float?371.0M
Float %?51.8%
P/E Ratio?N/A
P/B Ratio?4.54
EPS?-$0.42
Dividend?0.00%
Ex-Dividend?N/A
Roivant Sciences Ltd. Common Shares (ROIV) trades at $28.58 per share. Technicals currently rate "Sell" while our fundamental analysis reads "Neutral". Notable factors include a robust Altman Z-Score, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.
Technical & fundamental data as of Jun 5, 2026.
News
Profile
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Employees
721
Market Cap
20.6B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2021-10-01
Address
7TH FLOOR, 50 BROADWAY
LONDON, SW1H 0DB
Phone: 441-295-5950
LONDON, SW1H 0DB
Phone: 441-295-5950
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?23
Z-Score?100
Momentum?50
Short Sent.?40
Piotroski F-Score?3/9Weak
Altman Z-Score?30.24Safe
Confidence?60%Moderate
Short InterestHigh
Short % of Float?7.38%Elevated
Short Interest?27.4M
Days to Cover?5.7
Free Float371.0M
Avg Daily Volume4.8M
Settlement Date2026-05-15
Financial Health
Current Ratio?18.37Strong
Quick Ratio?18.37Strong
Cash Ratio?5.05Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score58/100
P/E?N/A▾
P/B?4.54FAIR▾
Peers100
S&P40
P/S?2,488.71HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-14.9CHEAP▾
S&P97
EV/Sales?2,316.89HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-6.6%WEAK▾
S&P10
ROA?-5.3%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-758558000
Enterprise Value?$19.1B
Fundamentals ratios updated end of day